Your browser doesn't support javascript.
loading
Single vocal cord irradiation for early-stage glottic cancer: Excellent local control and favorable toxicity profile.
Tans, Lisa; Al-Mamgani, Abrahim; Kwa, Stefan L S; Elbers, Jos B W; Keskin-Cambay, Fatma; Sewnaik, Aniel; Dorr, Maarten; Nout, Remi; Heemsbergen, Wilma.
Afiliação
  • Tans L; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands. Electronic address: l.tans@erasmusmc.nl.
  • Al-Mamgani A; Department of Radiation Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, the Netherlands. Electronic address: a.almamgani@nki.nl.
  • Kwa SLS; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands. Electronic address: s.kwa@erasmusmc.nl.
  • Elbers JBW; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands. Electronic address: j.elbers@erasmusmc.nl.
  • Keskin-Cambay F; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands. Electronic address: f.cambay@erasmusmc.nl.
  • Sewnaik A; Department of Otolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: a.sewnaik@erasmusmc.nl.
  • Dorr M; Department of Otolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: m.dorr@erasmusmc.nl.
  • Nout R; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands. Electronic address: r.nout@erasmusmc.nl.
  • Heemsbergen W; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands. Electronic address: w.heemsbergen@erasmusmc.nl.
Oral Oncol ; 127: 105782, 2022 04.
Article em En | MEDLINE | ID: mdl-35276637
OBJECTIVE: To validate the earlier reported promising oncologic outcomes and favorable toxicity profile following single vocal cord irradiation (SVCI) in an expanded cohort of patients with early-stage glottic cancer treated at our institute with longer follow-up time. MATERIALS AND METHODS: Between February 2011 and January 2020, 111 consecutive patients with early-stage glottic cancer were treated with SVCI to the whole involved vocal cord (58.08 Gy, given in 16 fractions of 3.63 Gy). Setup verification was done using cone-beam CT, prior to each fraction. The endpoints were local control (LC), overall survival (OS), grade ≥ 3 toxicity and voice quality assessment using voice-handicap index (VHI) questionnaires. RESULTS: Median follow-up was 41 months (range; 8-84). Two patients developed in-field local failure (LF). The 3- and 5-year LC rates were 99.1% and 97.1%, respectively. As both patients with LF were successfully salvaged with total laryngectomy, the 5-year ultimate LC-rates was 99%. The 5-years OS was 80.6%. All patients finished treatment without any interruption. No patients developed acute grade ≥ 3 toxicity. Late grade 3 toxicity was reported in 7 patients (6.5%) out of 108 patients evaluable for late toxicity; 2 because of severe hoarseness and 5 because of laryngeal radionecrosis (4.5%). The 5-years laryngectomy-free survival was 98.1%. The VHI-scores improved over time, only 22% of patients had VHI > 30 at 3-years post-radiotherapy, compared to 38% at baseline. CONCLUSIONS: Local control rate and laryngectomy-free survival of SVCI are excellent with favorable toxicity profile and good VHI-score. These results validate our early results.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prega Vocal / Neoplasias Laríngeas Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prega Vocal / Neoplasias Laríngeas Idioma: En Ano de publicação: 2022 Tipo de documento: Article